SlateStone Wealth LLC Raises Holdings in DexCom, Inc. (NASDAQ:DXCM)

SlateStone Wealth LLC boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 29.4% in the second quarter, Holdings Channel reports. The institutional investor owned 2,294 shares of the medical device company’s stock after acquiring an additional 521 shares during the period. SlateStone Wealth LLC’s holdings in DexCom were worth $260,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of DXCM. Crewe Advisors LLC purchased a new position in shares of DexCom in the 1st quarter worth approximately $29,000. DSM Capital Partners LLC purchased a new position in DexCom in the fourth quarter worth $28,000. Riverview Trust Co purchased a new position in DexCom in the first quarter worth $32,000. Smithfield Trust Co increased its position in shares of DexCom by 103.1% during the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after purchasing an additional 165 shares in the last quarter. Finally, Sound Income Strategies LLC lifted its holdings in shares of DexCom by 41.7% during the 1st quarter. Sound Income Strategies LLC now owns 340 shares of the medical device company’s stock valued at $47,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In related news, Director Bridgette P. Heller sold 1,000 shares of the firm’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the sale, the director now owns 25,349 shares in the company, valued at $2,878,378.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, Director Bridgette P. Heller sold 1,000 shares of the company’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the transaction, the director now owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Jon Brown sold 652 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the transaction, the executive vice president now owns 66,249 shares in the company, valued at approximately $4,607,617.95. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,135 shares of company stock worth $446,797. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Canaccord Genuity Group restated a “buy” rating and set a $145.00 price target on shares of DexCom in a research note on Tuesday, July 23rd. JPMorgan Chase & Co. lowered shares of DexCom from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $145.00 to $75.00 in a research report on Friday, July 26th. Piper Sandler reissued an “overweight” rating and set a $90.00 target price on shares of DexCom in a research report on Monday. Finally, UBS Group decreased their price target on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and an average target price of $112.25.

DexCom Price Performance

Shares of DXCM opened at $73.67 on Tuesday. The business’s 50-day moving average is $94.61 and its two-hundred day moving average is $115.90. The company has a market capitalization of $29.30 billion, a P/E ratio of 47.53, a P/E/G ratio of 2.18 and a beta of 1.16. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The company’s revenue was up 15.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.34 earnings per share. Research analysts predict that DexCom, Inc. will post 1.69 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.